Description
BSE announces allocation of 45,27,823 equity shares to 25 anchor investors at ₹593 per share for Sudeep Pharma Limited's IPO, raising ₹268.50 crore.
Summary
BSE has announced the allocation of equity shares to anchor investors for Sudeep Pharma Limited’s initial public offering (IPO). The Board of Directors finalized the allocation of 45,27,823 equity shares of face value ₹1 each to 25 anchor investors at an allocation price of ₹593 per share (including share premium of ₹592), raising a total of ₹268.50 crore in the anchor investor portion.
Key Points
- Total anchor allocation: 45,27,823 equity shares at ₹593 per share
- Total amount raised from anchors: ₹268.50 crore (₹2,68,49,99,039)
- Face value: ₹1 per equity share
- Share premium: ₹592 per equity share
- Number of anchor investors: 25 investors
- Domestic allocation: 36,05,799 shares (79.64% of anchor portion) to 14 domestic investors
- Book Running Lead Managers: ICICI Securities Limited and IIFL Capital Limited (formerly IIFL Securities Limited)
- Board meeting date: November 20, 2025
Major Anchor Investors
Largest Allocations (7.82% each):
- SBI Healthcare Opportunities Fund: 3,54,125 shares (₹21.00 crore)
- ICICI Prudential MNC Fund: 3,54,125 shares (₹21.00 crore)
- Nippon Life India Trustee Ltd - Nippon India Flexi Cap Fund: 3,54,125 shares (₹21.00 crore)
- Aditya Birla Sun Life Small Cap Fund: 3,54,125 shares (₹21.00 crore)
- Mirae Asset Healthcare Fund: 2,04,900 shares (₹12.15 crore)
Other Significant Allocations:
- Axis Multi Asset Allocation Fund: 2,65,600 shares (₹15.75 crore)
- HDFC Manufacturing Fund: 2,36,075 shares (₹14.00 crore)
- Multiple mutual funds and insurance companies with allocations ranging from 51,212 to 2,04,900 shares
Company Information
- Company Name: Sudeep Pharma Limited
- CIN: U24231GJ1989PLC013141
- Registered Office: 129/1/A, G.I.D.C. Estate Nandesari, Baroda-391340, Gujarat
- Corporate Office: 601-602, 6th Floor, Sears Towers-2, Gotri-Sevasi Road, Sevasi, Vadodara-390021, Gujarat
- Website: www.sudeepgroup.com
- Email: mail@sudeepgroup.com
- Phone: +91 265 2840656, 7624095107
Important Dates
- Board Meeting Date: November 20, 2025
- Anchor Investor Allocation Date: November 20, 2025
Impact Assessment
Market Impact:
- Strong institutional interest with participation from major mutual funds including SBI, HDFC, ICICI Prudential, Axis, Whiteoak Capital, and others
- Healthcare/pharma sector focus evident from specialized healthcare funds participation (SBI Healthcare, Mirae Asset Healthcare, UTI Healthcare)
- Broad diversification across fund categories: small cap, flexi cap, multi cap, manufacturing, and sector-specific funds
- Insurance participation from SBI Life and Tata AIA Life indicates confidence in the offering
For Investors:
- Anchor allocation represents institutional validation of the IPO pricing
- Price point at ₹593 per share serves as reference for retail and other investor categories
- Strong presence of quality institutional investors may indicate positive sentiment for main IPO
Sector Relevance:
- Pharmaceutical manufacturing sector company based in Gujarat
- Addition to listed pharma companies on BSE/NSE
- Potential index inclusion candidate post-listing
Impact Justification
Important IPO anchor allocation for pharmaceutical company, significant for investors tracking new listings and pharma sector, but limited broader market impact